Evidence-based patient safety advisory: malignant hyperthermia.
As more and more routine plastic surgery procedures move from the hospital to outpatient surgery facilities, plastic surgeons must be aware of the risk factors for life-threatening events that might occur in this setting. This awareness includes recognition of the signs and symptoms and the management of a rare but life-threatening condition, malignant hyperthermia. This article reviews the current understanding of the concepts pertinent to malignant hyperthermia diagnosis and treatment in the outpatient setting and current standards and recommendations for physicians and support personnel regarding malignant hyperthermia preparedness in office-based surgery and anesthesia.
Gurunluoglu
Raffi
R
Denver, Colo.; and Arlington Heights, Ill. From the Denver Health Medical Center and the American Society of Plastic Surgeons' Patient Safety Committee.
Swanson
Jennifer A
JA
Haeck
Phillip C
PC
D000556:Ambulatory Surgical Procedures; D000758:Anesthesia / Q000009:adverse effects; D019317:Evidence-Based Medicine; D006801:Humans; D008305:Malignant Hyperthermia / Q000175:diagnosis* / Q000628:therapy*; D018579:Patient Selection; D019651:Plastic Surgery Procedures; D012449:Safety
Denborough MA, Lovell RRH. Anesthetic deaths in a family. Lancet 1960;2:45.
Greenhalgh T. How to Read a Paper: The Basics of Evidence-Based Medicine. 3rd ed. Oxford: Blackwell Publishing; 2006.
Lang TA, Secic M. How to Report Statistics in Medicine. 2nd ed. Philadelphia: American College of Physicians; 2006.
Straus SE, Richardson WS, Glasziou P, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. 3rd ed. Philadelphia: Elsevier Churchill Livingstone; 2005.
Evidence-Based Medicine Working Group. Users’ Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice. Chicago: American Medical Association; 2002.
Adamson PA, Dahiya R, Litner J, Vosu H. Malignant hyperthermia: Successful management in a private surgery centre. J Otolaryngol. 2006;35:186–189.
Allen GC, Brubaker CL. Human malignant hyperthermia associated with desflurane anesthesia. Anesth Analg. 1998;86:1328–1331.
Shulman M, Braverman B, Ivankovich A, Gronert G. Sevoflurane triggers malignant hyperthermia in swine. Anesthesiology 1981;54:259–260.
Gronert GA. Malignant hyperthermia. Anesthesiology 1980;53:395–423.
Gallant EM, Gronert GA, Taylor SR. Cellular membrane potentials and contractile threshold in mammalian skeletal muscle susceptible to malignant hyperthermia. Neurosci Lett. 1982;28:181–186.
Gronert GA, Pessah IN, Muldoon SM, Tautz TJ. Malignant hyperthermia. In: Miller RD, ed. Miller’s Anesthesia. Vol. 1, 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2008:1169–1190.
McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat. 2000;15:410–417.
Ibarra MC, Wu S, Murayama K, et al. Malignant hyperthermia in Japan: Mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology 2006;104:1146–1154.
Robinson RL, Brooks C, Brown S, et al. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum Mutat. 2002;20:88–97.
Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet. 1997;60:1316–1325.
Monaghan A, Hindle I. Malignant hyperpyrexia in oral surgery: Case report and literature review. Br J Oral Maxillofac Surg. 1994;32:190–193.
King JO, Denborough MA, Zapf PW. Inheritance of malignant hyperpyrexia. Lancet 1972;1:365–370.
Jungbluth H. Central core disease. Orphanet J Rare Dis. 2007;2:25.
Jungbluth H. Multi-minicore Disease. Orphanet J Rare Dis. 2007;2:31.
Larach MG, Rosenberg H, Gronert G, Allen GC. Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Clin Pediatr (Phila.) 1997;36:9–16.
Murray C, Sasaki SS, Berg D. Local anesthesia and malignant hyperthermia: Review of the literature and recommendations for the dermatologic surgeon. Dermatol Surg. 1999;25:626–630.
Haas DA, Young ER, Harper DG. Malignant hyperthermia and the general dentist: current recommendations. J Can Dent Assoc. 1992;58:28–33.
Chang CY, Scher RL. Malignant hyperthermia and the otolaryngologist. Ear Nose Throat J. 2003;82:433–436.
Topel DG, Bicknell EJ, Preston KS, Christian LL, Matsushima CY. Porcine stress syndrome. Mod Vet Pract 1968;49:40–60.
Bendahan D, Kozak-Ribbens G, Confort-Gouny S, et al. A noninvasive investigation of muscle energetics supports similarities between exertional heat stroke and malignant hyperthermia. Anesth Analg. 2001;93:683–689.
Hackl W, Winkler M, Mauritz W, Sporn P, Steinbereithner K. Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced myolysis. Br J Anaesth. 1991;66:138–140.
Hopkins PM. Malignant hyperthermia: Advances in clinical management and diagnosis. Br J Anaesth. 2000;85:118–128.
Durham WJ, Racena-Parks P, Long C, et al. RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice. Cell 2008;133:53–65.
Bryson GL, Chung F, Cox R, et al. Patient selection in ambulatory anesthesia: An evidence-based review. Part II. Can J Anaesth. 2004;51:782–794.
Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.
Larach MG. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg. 1989;69:511–515.
Litman RS, Rosenberg H. Malignant hyperthermia: Update on susceptibility testing. JAMA. 2005;293:2918–2924.
Rosenberg H, Antognini JF, Muldoon S. Testing for malignant hyperthermia. Anesthesiology 2002;96:232–237.
Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand. 1997;41:955–966.
Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: A report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 1998;88:579–588.
Sei Y, Sambuughin NN, Davis E, et al. Malignant hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004;101:824–830.
Robinson R, Hopkins P, Carsana A, et al. Several interacting genes influence the malignant hyperthermia phenotype. Hum Genet. 2003;112:217–218.
Robinson RL, Anetseder MJ, Brancadoro V, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing? Eur J Hum Genet. 2003;11:342–348.
Urwyler A, Deufel T, McCarthy T, West S; European Malignant Hyperthermia Group. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth. 2001;86:283–287.
Girard T, Treves S, Voronkov E, Siegemund M, Urwyler A. Molecular genetic testing for malignant hyperthermia susceptibility. Anesthesiology 2004;100:1076–1080.
Rohrich RJ, White PF. Safety of outpatient surgery: Is mandatory accreditation of outpatient surgery centers enough? Plast Reconstr Surg. 2001;107:189–192.
Rohrich RJ. Patient safety first in plastic surgery. Plast Reconstr Surg. 2004;114:201–203.
Horton JB, Reece EM, Broughton G II, Janis JE, Thornton JF, Rohrich RJ. Patient safety in the office-based setting. Plast Reconstr Surg. 2006;117:61e–80e.
Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene: A review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004;59:364–373.
Wackym PA, Dubrow TJ, Abdul-Rasool I, Lesavoy MA. Malignant hyperthermia in plastic surgery. Plast Reconstr Surg. 1988;82:878–882.
Wedel DJ, Quinlan JG, Iaizzo PA. Clinical effects of intravenously administered dantrolene. Mayo Clin Proc. 1995;70:241–246.
Carr AS, Lerman J, Cunliffe M, McLead ME, Britt BA. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy. Can J Anaesth. 1995;42:281–286.
Hackl W, Mauritz W, Winkler M, Sporn P, Steinbereithner K. Anaesthesia in malignant hyperthermia-susceptible patients without dantrolene prophylaxis: A report of 30 cases. Acta Anaesthesiol Scand. 1990;34:534–537.
Baudendistel L, Goudsouzian N, Cote’ C, Strafford M. End-tidal CO2 monitoring: Its use in the diagnosis and management of malignant hyperthermia. Anaesthesia 1984;39:1000–1003.
Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982;56:254–262.
Paul-Pletzer K, Yamamoto T, Bhat M, et al. Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem. 2002;277:34918–34923.
Ikemoto N, Yamamoto T. Postulated role of inter-domain interaction within the ryanodine receptor in Ca(2+) channel regulation. Trends Cardiovasc Med. 2000;10:310–316.
Yamamoto T, Ikemoto N. Spectroscopic monitoring of local conformational changes during the intramolecular domain-domain interaction of the ryanodine receptor. Biochemistry 2002;41:1492–1501.
Kobayashi S, Bannister ML, Gangopadhyay J, Hamada T, Parness J, Ikemoto N. Dantrolene stabilizes domain interactions within the ryanodine receptor. J Biol Chem. 2005;280:6580–6587.
Murayama T, Oba T, Kobayashi S, Ikemoto N, Ogawa I. Postulated role of interdomain interactions within the type 1 ryanodine receptor in the low gain of Ca2+-induced Ca2+ release activity of mammalian skeletal muscle sarcoplasmic reticulum. Am J Physiol. 2005;288:C1222–C1230.
Larach MG, Localio AR, Allen G, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994;80:771–779.
Sambuughin N, Sei Y, Gallagher K, et al. North American malignant hyperthermia population: Screening of the ryanodine receptor gene and identification of novel mutations. Anesthesiology 2001;95:594–599.
Anderson AA, Brown RL, Polster B, Pollock N, Stowell KM. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia. Anesthesiology 2008;108:208–215.
Britt BA, Endrenyi L, Frodis W, Scott E, Kalow W. Comparison of effects of several inhalation anaesthetics on caffeine-induced contractures of normal and malignant hyperthermic skeletal muscle. Can Anaesth Soc J. 1980;27:12–15.
Reed SB, Strobel GE Jr. An in-vitro model of malignant hyperthermia: Differential effects of inhalation anesthetics on caffeine-induced muscle contractures. Anesthesiology 1978;48:254–259.
Flewellen EH, Nelson TE. Masseter spasm induced by succinylcholine in children: Contracture testing for malignant hyperthermia. Report of six cases. Can Anaesth Soc J. 1982;29:42–49.
Snoeck MM, Gielen MJ, Tangerman A, van Egmond J, Dirksen R. Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane. Acta Anaesthesiol Scand. 2000;44:334–337.
Gallant EM, Godt RE, Gronert GA. Mechanical properties of normal and malignant hyperthermia susceptible porcine muscle: Effects of halothane and other drugs. J Pharmacol Exp Ther. 1980;213:91–96.
Louis CF, Zualkernan K, Roghair T, Mickelson JR. The effects of volatile anesthetics on calcium regulation by malignant hyperthermia-susceptible sarcoplasmic reticulum. Anesthesiology 1992;77:114–125.
Nelson TE, Flewellen EH. Rationale for dantrolene vs. procainamide for treatment of malignant hyperthermia. Anesthesiology 1979;50:118–122.